Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carey Hwang

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Antiviral Therapy|August 22, 2013
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovirMarc Bifano, Carey Hwang, Berend Oosterhuis, et al.
Journal of the International AIDS Society|November 14, 2014
Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxoneTushar Garimella, Reena Wang, Wen-Lin Luo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 25, 2017
The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical IsolatesNeelanjana Ray, Tianbo Li, Zeyu Lin, et al.
Antiviral Therapy|February 6, 2015
Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairmentTushar Garimella, Reena Wang, Wen-Lin Luo, et al.
AIDS (London, England)|October 13, 2020
Changes in weight and BMI with first-line doravirine-based therapyChloe Orkin, Richard Elion, Melanie Thompson, et al.
Antimicrobial Agents and Chemotherapy|May 2, 2022
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to ResistanceMing-Tain Lai, Meizhen Feng, Min Xu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2020
Review of Doravirine Resistance Patterns Identified in Participants During Clinical DevelopmentElizabeth Anne Martin, Ming-Tain Lai, Winnie Ngo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2020
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority TrialChloe Orkin, Kathleen E Squires, Jean-Michel Molina, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2019
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety AnalysisMelanie Thompson, Chloe Orkin, Jean-Michel Molina, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2013
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutationsZhufang Li, Brian Terry, William Olds, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Antiviral Therapy|August 22, 2013
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovirMarc Bifano, Carey Hwang, Berend Oosterhuis, et al.
Journal of the International AIDS Society|November 14, 2014
Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxoneTushar Garimella, Reena Wang, Wen-Lin Luo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 25, 2017
The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical IsolatesNeelanjana Ray, Tianbo Li, Zeyu Lin, et al.
Antiviral Therapy|February 6, 2015
Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairmentTushar Garimella, Reena Wang, Wen-Lin Luo, et al.
AIDS (London, England)|October 13, 2020
Changes in weight and BMI with first-line doravirine-based therapyChloe Orkin, Richard Elion, Melanie Thompson, et al.
Antimicrobial Agents and Chemotherapy|May 2, 2022
Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to ResistanceMing-Tain Lai, Meizhen Feng, Min Xu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2020
Review of Doravirine Resistance Patterns Identified in Participants During Clinical DevelopmentElizabeth Anne Martin, Ming-Tain Lai, Winnie Ngo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2020
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority TrialChloe Orkin, Kathleen E Squires, Jean-Michel Molina, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2019
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety AnalysisMelanie Thompson, Chloe Orkin, Jean-Michel Molina, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2013
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutationsZhufang Li, Brian Terry, William Olds, et al.
Pageof 4